Table 2.
Patient Characteristics
| Patient Characteristics | SJMB96 – PF*RT – No Amifostine (n=35) | SJMB96 – PF* RT Amifostine (n=40) | SJMB03 – TBRT* Amifostine (n=22) |
|---|---|---|---|
| AGE AT STUDY ENROLLMENT | |||
| Median | 7.81 | 9.23 | 8.43 |
| Min | 3.18 | 4.09 | 3.43 |
| Max | 17.16 | 20.16 | 17.70 |
| SEX [N (percent)] | |||
| F | 16 (45.7) | 14 (35.0) | 9 (40.9) |
| M | 19 (54.3) | 26 (65.0) | 13 (59.1) |
| RACE [N (percent)] | |||
| Asian | 1 (2.9) | 0 | 1 (4.6) |
| Black | 4 (11.4) | 6 (15.0) | 2 (9.1) |
| Hispanic | 5 (14.3) | 3 (7.5) | 0 |
| Other | 0 | 4 (10.0) | 3 (13.6) |
| White | 25 (71.4) | 27 (67.5) | 16 (72.7) |
| Received Four Courses of Cisplatin [N (percent)] | 31 (88.6) | 35 (87.5) | 19 (86.4) |
| Cumulative Dose of Cisplatin per m2 [Median (range)] | 301.1 (76.7 – 308.9) | 299.9 (79.0 – 306.0) | 299.6 (186.9 – 304.4) |
| TOTAL | 35 | 40 | 22 |
†
PFRT = Posterior Fossa Irradiation, TBRT= Tumor Bed Irradiation